Figures 3.
a-d. Renal allograft survival was significantly worse with alemtuzumab induction in primary deceased donor (a), primary living donor (b), non-primary deceased donor (c), and non-primary living donor (d) renal allografts
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.